Infliximab treatment for resistant Achilles tendonitis.
Undifferentiated spondyloarthropathies USPA can sometimes be refractory to usual disease modifying agents. Anti-tumor necrosis factor TNF-alpha agents have been shown to be effective in spondyloarthropathies. Few articles described the efficacy of TNF-alpha antagonists in USPA. Our patient had refractory Achilles tendonitis as an early manifestation of USPA which responded dramatically to infliximab treatment.
Al-Asfar
Said M
SM
Department of Medicine, Division of Rheumatology, North West Armed Forces Hospital, Tabuk, Kingdom of Saudi Arabia. salasfar@hotmail.com
Attar
Mohammad
M
Shacfeh
Hasan
H
D000125:Achilles Tendon / Q000473:pathology*; D000328:Adult; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D008279:Magnetic Resonance Imaging; D008297:Male; D052256:Tendinopathy / Q000175:diagnosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab